Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

• the present invention relates to novel imidazolylethoxyindanes which have an effective antithrombotic activity, its pharmacologically-acceptable salts, and process for preparing the same.
• the present invention relates to novel imidazolylethoxyindanes represented by the general formula (I), ##STR2## wherein X is a C ⁇ O group, a CH--CN group or a CH--COOH group, and the ether group (--O--) is bonded to the indanic group in the 4-, 5- or 6-position thereof, its pharmacologically-acceptable salts and process for preparing the same.
• U.K. Pat. No. 2,038,821 discloses, among other compounds, 4-[2-(1H-imidazol-1-yl)ethoxy]benzoic acid (Dazoxiben) represented by the formula (A), ##STR3##
• Dazoxiben belongs to an interesting group of antithrombotic imidazoles which are characterised by their ability to selectively inhibit the thromboxane synthetase enzyme without significantly inhibiting the prostacyclin formation unlike conventional antithrombotic drugs, such as acetylsalicylic acid (B), ##STR4##
• Dazoxiben does not seem to be a decisive therapy for thrombotic diseases.
• ADP adenosine diphosphate
• the present invention is based on this finding.
• Acid addition salts include mineral acid salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide, phosphate, etc.; or organic acid salts such as acetate, maleate, fumarate, citrate or tartarate, etc.
• Non-limiting examples of the compounds of this invention include:
• novel compounds, imidazolylethoxyindanes, represented by the general formula (I) can be prepared by the following method: ##STR5##
• the hydroxylated indanones of general formula (II) are subjected to alkylation with a reagent of general formula Y-(CH 2 ) 2 -O-Z, wherein Y is an halogen atom selected from chlorine or bromine, and Z is a migrant group selected from alkylsulfonyl or arylsulfonyl groups.
• Y is an halogen atom selected from chlorine or bromine
• Z is a migrant group selected from alkylsulfonyl or arylsulfonyl groups.
• alkaline hydrides preferably sodium hydride
• the reaction procedure requires an inert and aprotic solvent, preferably N,N-dimethylformamide, and a suitable temperature ranging from 60° C. to the boiling point of the mixture.
• imidazolylethoxyindanones of general formula (I, X: C ⁇ O) are subject to react with (p-toluenesulfonyl)methyl-isocyanide in a ether-like solvent, preferably dimethoxyethane, and in the presence of a strong base, preferably an alkaline alcoxide dissolved in an alcohol having 4 carbon atoms at most, such as sodium ethoxide in ethanol, and at a temperature ranging from -10° to 40° C.
• a strong base preferably an alkaline alcoxide dissolved in an alcohol having 4 carbon atoms at most, such as sodium ethoxide in ethanol, and at a temperature ranging from -10° to 40° C.
• the starting hydroxylated indanones (II) may be prepared according to either conventional methods in Organic Chemistry or specific procedures disclosed in the literature. Consequently, 5-hydroxy-1-indanone was prepared by demethylation of 5-methoxy-1-indanone (commercially available) with aluminum bromide dissolved in dry methylene chloride under reflux (Example 13): ##STR6## In contrast, 4-hydroxy-1-indanone was prepared from coumarin (commercially available) by hydrogenation followed by internal Friedel-Craft's reaction (Rev.Soc.Quim.Mex., 11, 39, 1967; Ni-Raney preparation: J.Org.Chem., 26, 1625, 1961): ##STR7## 6-Hydroxy-1-indanone was prepared from 3-(4-methoxyphenyl)propionic acid (commercially available) by internal Friedel-Crafts' reaction (J.Am.Chem.Soc., 67, 1853, 1945) followed by demethylation with aluminum bromide dissolved in
• the compounds of the present invention have an effective antithrombotic activity as evidenced by their protective action against mortality and respiratory distress induced by endovenous sodium arachidonate in mice (Kohler C. et al: Thrombosis Research, 9, 67-80, 1976). It was observed in this test the specific activity of 5-[ ⁇ (1H-imidazol-1-yl)ethoxy]-indan-1-carboxylic acid hydrochloride showing 13.3 mg/kg DE 50 orally. Moreover, these compounds inhibit the in vitro platelet aggregation induced by ADP at 10 ⁇ M concentration in rat's richly-platelet plasma.
• the IC 50 of 5-[ ⁇ -(1H-imidazol-1-yl)ethoxy]indan-1-carboxylic acid is 2.5-5 ⁇ 10 -4 M.
• ADP as an aggregating agent, at a concentration of 2.5 ⁇ M in total blood of rats in vitro, an IC 50 of 7.1 ⁇ 10 -4 M was obtained for 5-[ ⁇ -(1H-imidazol-1-yl)ethoxy]indan-1-carboxylic acid while Dazoxiben HCl at this concentration only caused a 30% inhibition.
• the compounds of this invention are useful agents in the treatment of cardiovascular diseases, such as thrombosis, coronary contractions, arrhythmias, ischaemic cerebral attack, migraine, myocardial infarction, angina pectoris and hypertension; repiratory disorders, e.g. asthma and apnea; and inflammatory conditions of organs and limbs.
• cardiovascular diseases such as thrombosis, coronary contractions, arrhythmias, ischaemic cerebral attack, migraine, myocardial infarction, angina pectoris and hypertension
• repiratory disorders e.g. asthma and apnea
• inflammatory conditions of organs and limbs e.g. asthma and apnea
• the compounds of the present invention mixed with pharmaceutically acceptable carriers can be administered by the oral route in the form of tablets, capsules, coated tablets, syrups, solutions, etc., by injectable route and by rectal route at daily doses ranging from 0.01 to 200 mg/kg.
• the residue (71.6 g) is treated with water (250 ml) and methylene chloride (250 ml); the aqueous phase is extracted two further times with methylene chloride, and the organic extracts are washed twice with 100 ml of 10% sodium hydroxide and with water till neutralization.
• the solvent is evaporated and the residue (54 g) is purified over silica-gel column; by eluting with methylene chloride:hexane (9:1) the excess ⁇ -chloro-ethyl p-toluenesulphonate is separated, and the desired product is isolated with methylene chloride; 26.6 g (51%) of a yellow solid are obtained. M.P. 79°-82° C. and analysis correct.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8488410

Family Applications (1)

Country Status (8)

Cited By (3)

Families Citing this family (2)

Citations (1)

Family Cites Families (1)

• 1984
  • 1984-12-10 ES ES539074A patent/ES539074A0/es active Granted
• 1985
  • 1985-11-26 PH PH33094A patent/PH23727A/en unknown
  • 1985-11-26 ZA ZA859034A patent/ZA859034B/xx unknown
  • 1985-12-09 JP JP60276665A patent/JPS61155372A/ja active Granted
  • 1985-12-09 EP EP85115652A patent/EP0184809B1/en not_active Expired
  • 1985-12-09 DE DE8585115652T patent/DE3571978D1/de not_active Expired
  • 1985-12-09 CA CA000497142A patent/CA1261852A/en not_active Expired
  • 1985-12-09 US US06/807,432 patent/US4610998A/en not_active Expired - Lifetime

Patent Citations (1)

Also Published As

Similar Documents

Legal Events